MaxLinear, Inc.MXLNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank21
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P21
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
2025-7.37%
2024-16.44%
2023-9.09%
20226.47%
202154.70%
202083.11%
2019-18.02%
20187.31%
201714.31%
201614.45%